Roche Notches Up First Approval For CD20xCD3 Bispecific Lunsumio
Positioned As ‘Off-The-Shelf’ Rival To CAR-Ts
Executive Summary
Roche has gained approval for the first of its two bispecific therapies for lymphoma, but will face stiff competition from Genmab and AbbVie’s late-stage rival.
You may also be interested in...
In Competitive DLBCL Setting, Pfizer Goes Old School With Adcetris
The ECHELON-3 trial in third-line diffuse large B-cell lymphoma showed positive topline results regardless of CD30 expression, and the drug maker intends to take the data to the FDA.
Roche Launches Eylea Competitor Vabysmo In India On The Heels Of Ocrevus
Roche is stepping up its game in India with the launch of blockbuster Vabysmo (faricimab), closely on the heels of Ocrevus (ocrelizumab). It hopes to drive access for the nAMD and DME drug via government procurement and insurance schemes and tiered pricing.
Already Closing In On Imbruvica With Brukinsa, BeiGene Sets Its Sights On Another Hematology Blockbuster
BeiGene is seeing rapid growth thanks to Brukinsa’s head-to-head superiority in CLL to the leading BTK inhibitor, Imbruvica, and now the company aims to repeat that feat by taking on another blood cancer big-hitter, Venclexta.